<link rel="stylesheet" type="text/css" href="https://ubosquemoodle.unbosque.edu.co/theme/uebtheme/css/stylesUEB.css">
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js" type="text/javascript"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/dist/css/lightbox.min.css" />
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/dist/js/lightbox-plus-jquery.min.js" type="text/javascript"></script>
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js"></script>
<!-- ================== script ================== -->
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>
<!-- ================== lightbox ================== -->
<!-- ================== animate scroll ================== -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/animate.css/3.5.1/animate.min.css">
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/wow/1.1.2/wow.min.js"></script>
<!-- ================== fin animate scroll ================== -->
<!-- ================== css ================== -->
<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/css/styles.css" />
<link rel="stylesheet" type="text/css" href="../../css/styles.css">
<div class="curso-cc">
  <div class="container-fluid">
    <div class="row-fluid">
      <div class="content-cc">
        <div class="banner-home" id="banner-home"></div>
        <div id="menu"></div>
        <h2>Módulo 2 / <span>Epidemiología, diagnóstico y diagnóstico diferencial del Mieloma Múltiple</span></h2>
        <h3>9. Bibliografía</h3>
        <ol>
          <li>KylSteensma D.P., Kyle R.A. (2018) History of Multiple Myeloma. In: Wiernik P., Dutcher J., Gertz M. (eds) Neoplastic Diseases of the Blood. Springer, Cham</li>
          <li>Blood, Pure and Eloquent: A Story of Discovery, of People and of Ideas. Edited by Maxwell M. Wintrobe. New York: McGraw‐Hill, 1980.</li>
          <li>Alwall, N. (2009). Urethane in Multiple Myeloma I. Acta Medica Scandinavica, 144(2), 114–118. </li>
          <li>Holland James. A controlled trial of Urethane Treatment in Multiple Myeloma. Blood, vol 27, No3 (March), 1966.</li>
          <li>Alexanian R. Melphalan therapy for plasma cell myeloma. Blood. 1968; Jan;31 (1):1-10.</li>
          <li>Kyle R, Rajkumar V. Multiple Myeloma. Blood, 15 march 2008 volume 111, number 6 </li>
          <li>Kyle R.A., Steensma D.P. (2011) History of Multiple Myeloma. In: Moehler T., Goldschmidt H. (eds) Multiple Myeloma. Recent Results in Cancer Research, vol 183. Springer, Berlin, Heidelberg</li>
          <li>Ravi, P., Kumar, S. K., Cerhan, J. R., Maurer, M. J., Dingli, D. M., Ansell, S. M., & Rajkumar, S. V. (2018). Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer Journal, 8(3), [26].</li>
          <li>Gertz M., Dingli D. How we manage autologous Stem cell trasplantation for patients with multiple myeloma. Blood 2014 124:882-890</li>
          <li>Moreau et al. Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death. J Clin Oncol 2014. 32:2173-218</li>
          <li>Walker et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. June 2018.</li>
          <li>R Fonseca, S Abouzaid, M Bonafede, Q Cai, K Parikh, L Cosler, P Richardson, Trends in overall survival and costs of multiple myeloma, 2000-2014, Leukemia accepted article preview 23 December 2016 </li>
          <li>Baz R, Alemany C, Green R, Hussein MA. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer 2004; 101:790.</li>
          <li>Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900.</li>
          <li>Singhal S, Vickrey E, Krishnamurthy J, et al. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009; 114:38.</li>
          <li>Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51:878.</li>
          <li>Dimopoulos MA, Kastritis E, Terpos E. Non-secretory myeloma: one, two, or more entities? Oncology (Williston Park) 2013; 27:930.</li>
          <li>Chawla SS, Kumar SK, Dispenzieri A, et al. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol 2015; 95:57.</li>
          <li>Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma. N Engl J Med 2012; 367:580.</li>
          <li>Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538.</li>
          <li>Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365:474.</li>
          <li>World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li>
          <li>Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33:657.</li>
          <li>Hillengass J, Moulopoulos LA, Delorme S, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J 2017; 7:e599.</li>
          <li>Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005; 184:1199.</li>
          <li>Shortt CP, Gleeson TG, Breen KA, et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 2009; 192:980.</li>
          <li>Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335:91.</li>
          <li>Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875.</li>
          <li>Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104:3052.</li>
          <li>Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 2015; 16:1617.</li>
          <li>Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24:929.</li>
          <li>Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101:2144.</li>
          <li>Lévy V, Katsahian S, Fermand JP, et al. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore) 2005; 84:250.</li>
          <li>Dhakal B, Szabo A, Chhabra S, et al. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:343.</li>
          <li>Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017; 376:1311.</li>
          <li>Lahuerta JJ, Grande C, Martínez-Lopez J, et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea phase II trial. Br J Haematol 2003; 120:296.</li>
          <li>Fassas AB, Barlogie B, Ward S, et al. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol 2003; 123:484.</li>
          <li>Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135:158.</li>
          <li>Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138:176.</li>
          <li>Corso A, Mangiacavalli S, Barbarano L, et al. Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged &lt;65 years. Cancer 2007; 109:2273.</li>
          <li>Jacobson J, Barlogie B, Shaughnessy J, et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 122:430.</li>
          <li>Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495.</li>
          <li>Stadtmauer EA. Multiple myeloma, 2004--one or two transplants? N Engl J Med 2003; 349:2551.</li>
          <li>Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25:2434.</li>
          <li>Naumann-Winter F, Greb A, Borchmann P, et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012; 10:CD004626.</li>
          <li>Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101:100.</li>
          <li>Stadtmauer EA, Pasquini MC, Blackwell B, et al. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autoHCT with len maintenance (TAM) and autoHCT with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial) (late breaking abstract 1). Blood 2016.</li>
          <li>Björkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88:4711.</li>
          <li>Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12:1195.</li>
          <li>Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017; 28:228.</li>
          <li>Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366:1759.</li>
          <li>Palumbo A, Gay F, Cavallo F, et al. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol 2015; 33:3459.</li>
          <li>Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol 2017; 3:28.</li>
          <li>Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014; 32:587.</li>
          <li>Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063.</li>
          <li>Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458.</li>
          <li>Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113:4137.</li>
          <li>Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114:772.</li>
          <li>Madan S, Lacy MQ, Dispenzieri A, et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011; 118:1763.</li>
          <li>Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123.</li>
          <li>Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133.</li>
          <li>Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23:2147.</li>
          <li>Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.</li>
          <li>Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47:1466.</li>
          <li>Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123:1826.</li>
          <li>Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 2013; 122:2799.</li>
          <li>Baz RC, Martin TG 3rd, Lin HY, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 2016; 127:2561.</li>
          <li>Jaslow R, Kaplan G, Lyons L, et al. Thalidomide in multiple myeloma--from the clinic to the laboratory. Cancer Invest 2002; 20:1051.</li>
          <li>Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102:69.</li>
          <li>Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79:875.</li>
          <li>Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132:584.</li>
          <li>Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48:46.</li>
          <li>van Rhee F, Dhodapkar M, Shaughnessy JD Jr, et al. First thalidomide clinical trial in multiple myeloma: a decade. Blood 2008; 112:1035.</li>
          <li>Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121:768.</li>
          <li>Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117:508.</li>
          <li>Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002; 112:412.</li>
          <li>Johnson DC, Corthals SL, Walker BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011; 29:797.</li>
          <li>Fakhouri F, Guerraoui H, Presne C, et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 2004; 125:96.</li>
          <li>Harris E, Behrens J, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003; 122:160.</li>
          <li>Dispenzieri A. Bortezomib for myeloma -- much ado about something. N Engl J Med 2005; 352:2546.</li>
          <li>Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 113:765.</li>
          <li>Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008; 143:537.</li>
          <li>Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22:1419.</li>
          <li>Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892.</li>
          <li>Ning YM, He K, Dagher R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park) 2007; 21:1503.</li>
          <li>Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008; 26:4777.</li>
          <li>Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22:2247.</li>
          <li>Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012; 97:1925.</li>
          <li>Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008; 112:1529.</li>
          <li>Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745.</li>
          <li>Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109:2604.</li>
          <li>San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008; 22:842.</li>
          <li>United States Food and Drug Administration<a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm" target="_blank">   http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm </a>(Accessed on February 01, 2010).</li>
          <li>Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119:5661.</li>
          <li>Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372:142.</li>
          <li>Stewart AK, Dimopoulos MA, Masszi T, et al. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol 2016.</li>
          <li>Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2018; 36:728.</li>
          <li>Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol 2017; 177:404.</li>
          <li>Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17:27.</li>
          <li>Chng WJ, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia 2017; 31:1368.</li>
          <li>Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18:1327.</li>
          <li>Dimopoulos M, Siegel D, White DJ, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood 2018.</li>
          <li>Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013; 27:1707.</li>
          <li>Kumar SK, LaPlant BR, Reeder CB, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood 2016; 128:2415.</li>
          <li>Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood 2017; 130:2610.</li>
          <li>Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol 2018.</li>
          <li> <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf" target="_blank">  http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf </a>(Accessed on November 20, 2015).</li>
          <li> <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf?et_cid=38631227&amp;et_rid=931330620&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2016%2f761036s004lbl.pdf" target="_blank">   http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf?et_cid=38631227&et_rid=931330620&linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2016%2f761036s004lbl.pdf </a>(Accessed on November 21, 2016).</li>
          <li>Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015; 373:1207.</li>
          <li>Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016.</li>
          <li>Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 2016; 128:37.</li>
          <li>Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:754.</li>
          <li>Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:1319.</li>
          <li>Plesner T, Arkenau HT, Gimsing P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 2016.</li>
          <li>Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 2015; 373:621.</li>
          <li>Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 2017; 178:896.</li>
          <li>Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2018; 379:1811.</li>
          <li>Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood 2016; 127:2833.</li>
          <li>San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15:1195.</li>
          <li>Richardson PG, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 2016; 127:713.</li>
          <li>Reece DE, Masih-Khan E, Atenafu EG, et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol 2015; 168:46.</li>
        </ol>
        <div class="progreso">
          <h2>Progreso módulo</h2>
          <div id="progreso100"></div>
        </div>
      </div>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid wow fadeInUp material-modulo">
      <div id="material-mod-2"></div>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid">
      <div class="span" id="footer-2"></div>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid wow fadeInUp codigo-modulo">
      <p class="small">Modulo 2: CO/ONC/1902/0002d – Diagnóstico y estadificación - Linfoma</p>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid">
      <ul class="pager">
        <li class="previous"><a class="available" href="https://ubosquemoodle.unbosque.edu.co/mod/page/view.php?id=291967">Anterior</a></li>
        <li class="next"><a class="disabled" href="#">Siguiente</a></li>
      </ul>
    </div>
  </div>
</div><!-- ================== script ================== -->
<script src="../../Menu/menu.js" type="text/javascript"></script>
<script src="../../Menu/timeit.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/Menu/menu.js" type="text/javascript"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/Menu/timeit.js" type="text/javascript"></script>
<!-- ================== fin script ================== -->
<script src="jquery.min.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/iframe-code/set-iframe-height-child.js"></script>
<script type="text/javascript">$(document).ready(function() {$("#single_1").fancybox({helpers: {title : {type : 'float'}}	});});</script>
<script type="text/javascript">$(".menu-toggle").click(function() {$("nav > ul").slideToggle( "700");$("nav > ul").css('display','flex');});</script>
<!-- ================== script animate scroll ================== -->
<script type="text/javascript">new WOW().init();</script>
<!-- ================== fin script animate scroll ================== -->
<script src="http://code.jquery.com/jquery.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/2.3.2/js/bootstrap.min.js"></script>